Feb 21 2007
Neurogen Corporation (Nasdaq: NRGN), a small molecule drug discovery and development company, announced today that it has appointed three executives to positions as vice president: Arunee Changchit, Vice President, Drug Metabolism and Pharmacokinetics; Jeffrey Dill, Vice President, General Counsel and Secretary; and Ricardo Ochoa, Vice President, Preclinical Safety.
Dr. Changchit leads the Drug Metabolism and Pharmacokinetics department at Neurogen.
Mr. Dill has assumed responsibility for all legal affairs of the Company. In addition to his responsibilities as General Counsel, he is also responsible for the Intellectual Property, Facilities Management and Health, Environment, and Safety departments.
Dr. Ochoa is responsible for Drug Safety and Toxicology, ensuring that each of the Neurogen's drug programs is supported with the technical and strategic expertise to execute appropriate toxicology studies and to evaluate drug safety matters. He is also responsible for seeking appropriate enabling technologies and biomarker strategies that will enhance Neurogen's research and development capabilities.
|
